Brief: Adial Pharmaceuticals Receives Notice Of Allowance On U.S. Patent For Treatment For Opioid Use Disorder Using Ad04
24/01/2022 14:48
Jan 24 (Reuters) - Adial Pharmaceuticals Inc ADIL.O :
* ADIAL PHARMACEUTICALS RECEIVES NOTICE OF ALLOWANCE ON U.S.
PATENT FOR TREATMENT FOR OPIOID USE DISORDER USING AD04
* ADIAL PHARMACEUTICALS RECEIVES NOTICE OF ALLOWANCE ON U.S.
PATENT FOR THE TREATMENT FOR OPIOID USE DISORDER USING AD04
* ADIAL PHARMACEUTICALS INC - ISSUED PATENT WOULD HAVE A
TERM THAT
EXPIRES NO EARLIER THAN JULY 1, 2031
Source text for Eikon: ID:nGNX2f25Zq
Further company coverage: ADIL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adial Pharmaceuticals
See all newsBrief: Adial Pharmaceuticals Announces Name Change To Azora Therapeutics
Brief: Adial Pharmaceuticals Announces Planned Appointment Of Celia Economides As Chief Financial Officer
Brief: Adial Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Adial Pharmaceuticals - Proposed Resale Of Up To 25,148,970 Shares Of Common Stock By Selling Stockholders - SEC Filing
Brief: Adial Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)